These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 29708235)
21. The immunology of Leishmania infection and the implications for vaccine development. Vanloubbeeck Y; Jones DE Ann N Y Acad Sci; 2004 Oct; 1026():267-72. PubMed ID: 15604504 [TBL] [Abstract][Full Text] [Related]
26. Genetically modified live attenuated vaccine: A potential strategy to combat visceral leishmaniasis. Pandey SC; Kumar A; Samant M Parasite Immunol; 2020 Sep; 42(9):e12732. PubMed ID: 32418227 [TBL] [Abstract][Full Text] [Related]
27. Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis. Didwania N; Shadab M; Sabur A; Ali N Front Immunol; 2017; 8():1779. PubMed ID: 29312309 [TBL] [Abstract][Full Text] [Related]
28. Leishmaniasis. Pace D J Infect; 2014 Nov; 69 Suppl 1():S10-8. PubMed ID: 25238669 [TBL] [Abstract][Full Text] [Related]
29. The History of Live Attenuated Volpedo G; Bhattacharya P; Gannavaram S; Pacheco-Fernandez T; Oljuskin T; Dey R; Satoskar AR; Nakhasi HL Pathogens; 2022 Apr; 11(4):. PubMed ID: 35456106 [TBL] [Abstract][Full Text] [Related]
30. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice. Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953 [TBL] [Abstract][Full Text] [Related]